Healio Minute

In this edition, screening program identifies airways disease in previously undiagnosed COPD, positive results show benefits of subcutaneous bispecifics and more. Read the full coverage here: Lung cancer screening program identifies airways disease in previously undiagnosed COPD Positive results in lung cancer show benefits of subcutaneous bispecifics Adagrasib delays progression of pretreated KRA...

In this edition, AI model helps predict anti-VEGF response in DME, Merck to acquire EyeBio and more. Read the full coverage here: VIDEO: AI model helps predict anti-VEGF response in diabetic macular edema Merck to acquire EyeBio VIDEO: IOP remains stable up to 48 weeks with aflibercept 8 mg for DME Phase 2 study of potential DME oral therapy meets primary endpoints FDA approves aflibercept biosimi...

In this edition, difficult-to-treat psoriatic arthritis 'not all about the therapies', Samsung biosimilar comparable to etanercept and more. Read the full coverage here: Difficult-to-treat psoriatic arthritis 'not all about the therapies' Samsung biosimilar comparable to etanercept for psoriatic arthritis outcomes at 1 year Boehringer Ingelheim, Quallent partner to expand Humira biosimilar access...

In this edition, smoking cessation support uptake at lung cancer screenings, glecirasib may deliver 'efficacy and tolerability advantages' and more. Read the full coverage here: Uptake of smoking cessation support high when offered at lung cancer screening Glecirasib may deliver 'efficacy and tolerability advantages' for KRAS-mutant lung cancer 'Substantial geographic disparities' worsening in can...

In this edition, FDA accepts new drug application for Eluminex, most mentors in vitreoretinal subspecialty are men and more. Read the full coverage here: FDA accepts investigational new drug application for Eluminex DME treatment Most mentors in vitreoretinal subspecialty are men Carotid artery stenosis linked to retinal changes in patients with diabetic retinopathy AI-assisted technology makes re...

In this edition, FDA approves Selarsdi as Stelara biosimilar, deucravacitinib improves 'broad range' of patient-reported outcomes and more. Read the full coverage here: FDA approves Selarsdi as Stelara biosimilar for psoriasis, psoriatic arthritis Deucravacitinib improves 'broad range' of patient-reported psoriatic arthritis outcomes Advanced therapy not enough for nearly 75% of Canadian patients...

In this edition, durvalumab improves survival in limited-stage small cell lung cancer, most adults do not test homes for radon exposure and more. Read the full coverage here: Durvalumab improves survival in limited-stage small cell lung cancer Survey: Most adults do not test homes for radon exposure, unconcerned about risks FDA fast tracks investigational bispecific therapy for aggressive lung can...

In this edition, PALADIN study navigates IOP-lowering surgery in DME patients, small-molecule eye drop well-tolerated as treatment for retinal vascular diseases and more. Read the full coverage here: PALADIN study: Navigating IOP-lowering surgery in DME patients for optimal outcomes Small-molecule eye drop safe, well-tolerated as treatment for retinal vascular diseases VIDEO: Reduction of vascular...

In this edition, race identified as risk factor for VTE, FDA approves Rybrevant for treatment of non-small cell lung cancer and more. Read the full coverage here: Race identified as risk factor for VTE after pulmonary resection for lung cancer FDA approves Rybrevant for treatment of non-small cell lung cancer Behavioral health disorders have a 'big impact' on cancer surgery outcomes Optimizing imm...

In this edition, blood test for lung cancer patients who may benefit from further immunotherapy, invasive procedures following lung cancer screenings and more. Read the full coverage here: Blood test identifies those with lung cancer who may benefit from further immunotherapy Invasive procedures rarely follow false-positive lung cancer screenings Study: Positive associations found between smoking...

In this edition, FDA places hold on cell therapy trial after patient death, selpercatinib delivers superior outcomes and more. Read the full coverage here: FDA places hold on trial of cell therapy for lung cancer after patient death Selpercatinib delivers superior outcomes , may 'reduce the burden of NSCLC' First-line immunotherapy benefits patients of all races with NSCLC equally Never-smoker lun...

In this edition, an advocacy group petitions the FDA for stronger safety warnings for Botox, melanoma regression is associated with improved prognosis and more. Read the full coverage here: Advocacy group petitions FDA for stronger safety warnings for Botox, related drugs Melanoma regression associated with improved prognosis Phase 4 results show Vtama cream efficacious in head, neck plaque psoria...

In this edition, allergic illnesses in children may be inherited from mothers; addressing needs of Muslim patients in dermatology; YouTube content on topical steroid withdrawal exhibits poor reliability and more. Read the full coverage here: Atopic dermatitis, other allergic illnesses in children may be inherited from mothers Addressing needs of Muslim patients in dermatology YouTube content on to...

In this edition, dermatologists 'uniquely positioned' to aid human trafficking victims; FDA approves Cosentyx for hidradenitis suppurativa and more. Read the full coverage here: Dermatologists 'uniquely positioned' to recognize, aid human trafficking victims FDA approves Cosentyx as first IL-17A inhibitor for hidradenitis suppurativa FDA approves Stelara biosimilar for treatment of psoriasis, mult...

In this edition, multicancer detection tests show promise; lifestyle counseling appointments benefit cancer survivors; use of low-value drugs for patients with cancer, and more. Read the full coverage here: Multicancer detection tests show promise, but questions linger about their accessibility Shared medical appointments for lifestyle counseling benefit cancer survivors Industry payments to physi...

In this edition, FDA approves Bimzelx for plaque psoriasis; roflumilast foam improves quality of life in patients with seborrheic dermatitis and more. Read the full coverage here: FDA approves Bimzelx for treatment of moderate to severe plaque psoriasis Roflumilast foam improves quality of life in patients with seborrheic dermatitis Opzelura effective, well tolerated in children aged at least 2 ye...

In this edition, FDA issues complete response letter for relabotulinumtoxinA; mucocutaneous manifestations may signal COVID-induced inflammatory disease in children and more. Read the full coverage here: FDA issues complete response letter for relabotulinumtoxinA for frown lines, crow's feet Mucocutaneous manifestations may signal COVID-induced inflammatory disease in children FDA approves Zoryve...

In this edition, precision navigators reduce racial disparities in genomic testing; cancer diagnoses fell sharply during early days of pandemic; Prostate Cancer Awareness Month updates, and more. Read the full coverage here: Precision navigators reduce racial disparities in genomic testing for prostate cancer Cancer diagnoses fell sharply during early days of pandemic, NCI report shows Prostate Ca...

In this edition, retinoids and OTC products for photoaged skin; fractional lasers show promise in skin cancer prevention; a botanical drug for severe thermal burns and more. Read the full coverage here: P rescription retinoids, OTC products positively impact photoaged skin Fractional lasers show promise in skin cancer prevention Botanical drug may outperform standard of care for treatment of sever...

In this edition, CDC issues a health advisory concerning flesh-eating bacterium, staging for melanoma does not represent accurate recurrence and mortality and more. Read the full coverage here: CDC issues health advisory about recent reports of fatal Vibrio vulnificus Study finds melanoma treatment costs have increased, but so has survival Melanoma staging system inaccurately reflects recurrence,...

In this edition, nearly $1 million in grants to aid diversity, equity, inclusion research; topical halcinonide may benefit patients with psoriasis; Asian patients may experience earlier mycosis fungoides diagnosis and more. Read the full coverage here: Nearly $1 million in grants to aid dermatology research in diversity, equity, inclusion Topical halcinonide may benefit patients with psoriasis wit...

In this edition, 'equitable access' to care may reduce racial disparities in survival; exercise may improve sexual function among men with prostate cancer; image-guided adaptive prostate radiation therapy for short-term toxicities, and more. Read the full coverage here: 'Equitable access' to care may reduce racial disparities in prostate cancer survival Exercise may improve sexual function among m...

In this edition, M-PDT efficacy similar to isotretinoin in acne vulgaris; Spitz neoplasm diagnosis in adults; immunotherapy treatment shows promise in basal cell carcinoma and more. Read the full coverage here: M-PDT efficacy similar to isotretinoin in acne vulgaris Clinicians should not 'shy away' from a Spitz neoplasm diagnosis in adults Novel nonsurgical immunotherapy treatment shows promise in...

In this edition, nonalcoholic muscadine wine may improve aging skin; atopic disease risk increases in sexually diverse patients; AI doubles diagnostic accuracy among patients with skin of color and more. Read the full coverage here: Nonalcoholic muscadine wine may improve aging skin in older women Atopic disease risk increases in sexually diverse patients AI doubles diagnostic accuracy of skin con...

In this edition, FDA approves Vanflyta for newly diagnosed AML; liso-cel could have 'best shot' at remission for double refractory CLL; mortality factors among cancer survivors and more. Read the full coverage here: FDA approves Vanflyta for newly diagnosed acute myeloid leukemia VIDEO: Liso-cel could have 'best shot' at remission for double refractory CLL Community affluence, insurance mediate CV...